Indeed, it was shown that high CDK12 expression is associated with disease recurrence and poor survival and activates WNT1- and WNT2-mediated Wnt/β-catenin signalling cascades to enhance stemness of HER2+ BC and, in turn, to induce trastuzumab resistance [67]. Here, ERBB2 is linked to breast cancer.